Biosensor
/ˈbʌɪə(ʊ)ˌsɛnsə/
A device that uses a living organism or biological molecules, especially enzymes or antibodies, to detect the presence of chemicals.
What are biosensors?
You might have seen people using a glucometer for routine glucose monitoring, fingertip pulse oximeters for measuring oxygen saturation levels and pulse rate, and smartwatches for daily monitoring of their physical activity.
These glucometers, pulse oximeters, and smartwatches are all examples of biosensors.
What do we do?
We are a student team from the University of Twente, Netherlands. And we compete in an international competition yearly hosted by SensUs to develop a biosensor to solve real-life medical challenges.
Each year, different student teams across the globe compete in this competition to design and develop a biosensor to meet the industry standards of biosensors.
Who or what is SensUs?
SensUs is an organisation run by students from Eindhoven University of Technology. The aim is to contribute to the future of health.
BIOSENSORS DEVELOPED BY BIOSENSING TEAM TWENTE
2023 Team – Traumatic brain injury
2023 Project
GFAP is a biomarker for Traumatic Brain Injury (TBI). It can reach high concentrations in TBI, resulting in physical, cognitive, social, emotional, and behavioral symptoms. Outcomes can range from complete recovery to permanent disability or death.
2024-2025 Team – Acute Kidney Injury (AKI)
2024 -2025 project
Creatinine is a key biomarker for Acute Kidney Injury (AKI). Elevated levels indicate impaired kidney function, which can lead to fluid retention, electrolyte imbalances, and toxin buildup. If left untreated, AKI can progress to chronic kidney disease or other severe complications. Early detection through continuous monitoring is crucial for improving patient outcomes.
2026 Team – Parkinson’s Disease
2026 project
Levodopa is the main biomarker in the treatment of Parkinson’s disease. Its concentration can fluctuate throughout the day, affecting symptom control and potentially causing side effects when levels become too low or too high. Our 2026 project focuses on developing a biosensor for continuous levodopa monitoring in interstitial skin fluid, with the goal of supporting more personalized treatment and improving quality of life for people living with Parkinson’s disease.